67 completed, 14 terminated, 9 unknown, 5 withdrawn. 52 Phase 2, 18 Phase 4, 12 Phase 3, 10 Phase 1, 7 Not applicable.
Follow Deferasirox: new trials by email Literature Review of Deferasirox trials Research Report on Deferasirox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major) | Phase 2 | Completed | Ain Shams University | 100 | 2026-01-01 | 2026-10-07 |
| Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation Iron chelation, Potato Resistant Starch - Allogeneic Stem Cell Transplant | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 50 | 2025-10-15 | 2026-07-21 |
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease | Phase 2 | Recruiting | Inova Health Care Services | 100 | 2025-10-07 | 2026-09-09 |
| Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study Luspatercept, Luspatercept combine with Deferasirox - Transfusion-dependent Non-severe Aplastic Anemia | Not applicable | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | 90 | 2025-05-20 | 2025-05-11 |
| Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload Deferasirox (DFX), Deferoxamine (DFO) - Pateints of β-thalassemia Major With Iron Overload | Not applicable | Completed | RESnTEC, Institute of Research | 142 | 2023-01-01 | 2024-06-21 |
| Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease Deferasirox 360 MG - Sickle Cell Disease | Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 12 | 2021-07-20 | 2023-02-13 |
| Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT Deferasirox - Iron Overload | Completed | University of Pisa | 39 | 2020-09-30 | 2025-06-03 | |
| Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS Deferasirox - Myelodysplastic Syndromes | Phase 2 | Terminated | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 11 | 2019-10-04 | 2022-11-21 |
| Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation DST-0509, Jadenu, Exjade - Thalassemia Major | Phase 2 | Completed | DisperSol Technologies, LLC | 25 | 2019-08-20 | 2022-02-01 |
| Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents Deferasirox - Myelodysplasia | Phase 2 | Completed | University Hospital, Grenoble | 39 | 2018-02-20 | 2024-12-16 |
| Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Deferasirox - Iron Overload | Phase 4 | Completed | Novartis Pharmaceuticals | 44 | 2018-01-16 | 2020-08-25 |
| The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) Deferasirox and calcium-vitamin D3, Calcium-vitamin D3 - Postmenopausal Osteoporosis | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 10 | 2018-01-15 | 2018-05-17 |
| Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH) Deferasirox FCT, Phlebotomy - Hereditary Hemochromatosis | Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2018-01-11 | 2024-10-09 |
| Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet Deferasirox dispersable tablet (DT), Deferasirox film coated tablet (FCT) - Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia | Phase 2 | Completed | Novartis Pharmaceuticals | 148 | 2017-07-27 | 2021-10-04 |
| Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome Deferasirox, Laboratory Biomarker Analysis - Anemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 2 | 2017-03-02 | 2020-07-01 |
| Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation Deferasirox - Chronic Iron Overload | Phase 3 | Completed | Novartis Pharmaceuticals | 53 | 2016-08-16 | 2020-03-03 |
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. Bone marrow aspirate, Deferasirox - Myelodysplastic Syndrome | Phase 2 | Terminated | Novartis Pharmaceuticals | 1 | 2016-05-30 | 2018-08-23 |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens Cytarabine, Deferasirox - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Unknown | Isfahan University of Medical Sciences | 40 | 2016-05-01 | 2016-02-25 |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation EXJADE - Myeloid Leukemia, Myelodysplastic Syndromes | Unknown | Hospices Civils de Lyon | 150 | 2016-04-01 | 2018-09-06 | |
| Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major Al-hijamah, Deferasirox - AL-Hijama in Thalassmia Major | Not applicable | Unknown | Tanta University | 60 | 2015-11-01 | 2017-04-25 |
Showing 20 of 98. Sign in to see all of them.
Iron Overload (41) · Myelodysplastic Syndromes (24) · Thalassemia (21) · beta-Thalassemia (17) · Anemia, Sickle Cell (9) · Anemia (7) · Anemia, Diamond-Blackfan (6) · Hemosiderosis (6) · Leukemia, Myeloid, Acute (5) · Hemochromatosis (4) · Multiple Myeloma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Primary Myelofibrosis (3) · Anemia, Aplastic (2) · Anemia, Refractory (2)
Novartis Pharmaceuticals (50) · Novartis (5) · Ain Shams University (2) · Abramson Cancer Center at Penn Medicine (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Children's Hospital (1) · Children's Hospital Los Angeles (1) · Children's Hospital of Philadelphia (1) · China Medical University Hospital (1) · City of Hope Medical Center (1) · Consorzio per Valutazioni Biologiche e Farmacologiche (1) · Crolll Gmbh (1) · DisperSol Technologies, LLC (1) · Elizabeth Henry (1)
United States (36) · Italy (27) · United Kingdom (15) · France (14) · Canada (13) · Egypt (13) · Germany (12) · Greece (12) · Thailand (12) · Turkey (Türkiye) (11) · Lebanon (10) · Spain (9) · Belgium (8) · China (7) · Russia (6)
Alexis Thompson, MD (1) · Ali Taher, Ass.Prof. (1) · Alireza Eishi, Med student (1) · Amit Pandya, M.D. (1) · Ariel Koren, MD (1) · Aurelio Maggio, MD (1) · Bart Scott (1) · Brad Spellberg, MD (1) · Deborah Chirnomas, MD (1) · Deybach Jean-Charles, Professor (1) · Donato Bonifazi, Dr (1) · Dr. Gianluca Forni (1) · Dr. Yves Bertrand (1)
PMID 37975597, PMID 17233848, PMID 17951527, PMID 19724055, PMID 19951979, PMID 19996412, PMID 20226990, PMID 20421274, PMID 20421452, PMID 20424435, PMID 20566896, PMID 21071497, PMID 21393329, PMID 21628399, PMID 21937481, PMID 22547607, PMID 22875626, PMID 22911183, PMID 23073603, PMID 23151373, PMID 23553596, PMID 23585526, PMID 23637051, PMID 24385534, PMID 24976388, PMID 24997153, PMID 25204541, PMID 25212456, PMID 25345697, PMID 25402221, PMID 25600572, PMID 25691036, PMID 25934475, PMID 26138856, PMID 26367238, PMID 27537786, PMID 29155313, PMID 30453981, PMID 32203980, PMID 32470438, PMID 32793403, PMID 33926431, PMID 34452199
2016 (3), 2004 (2), 2009 (2), P30CA015704 (1)